What Type of Lesions Are These?


Most patients experience progressive spread of eruption over several years.
VOLUME: 13 PUBLICATION DATE: Jun 15 2005
Sidebars_in_article: 

Histopathology

Article Reference: 

Syringomas are dermal tumors comprised of small ducts of cuboidal cells with moderately eosinophilic cytoplasm, along with cords of basophilic epithelial cells set in a fibrous stroma creating a “tadpole” appearance. The ducts, lined by rows of epithelial cells, may contain a keratinous substance in their lumina. Sclerosis of collagen, lymphomonocytic perivascular infiltrates and varying degrees of granulomatous foreign body-like reactions may be observed.7
A clear cell, periodic acid-Schiff positive variant with glycogen deposition within ducts
has also been described in association with diabetes.20,24 Higher rates of clear cell syringoma have been reported in Japan, where the disease bears a striking relationship to diabetes.20 Calcium deposits within syringeal structures have been identified by electron microscopy, and have previously been postulated to play an etiologic role in development of MICC in Down syndrome patients.10
Histologic, histochemical and electron microscopic analysis of two patients with eruptive syringoma19 were almost identical to those of common syringomas. Electron microscopy identified varying degrees of degeneration of cell walls consistent with continuous lysosome-mediated remodeling of cellular structures in lesional skin. Monoclonal antibody studies comparing eyelid and eruptive forms of syringoma demonstrated essentially identical tumors derived from eccrine ducts.25
A recent observation of eruptive syringoma-like reactions from cutaneous eczematous processes prompted the theory that eruptive syringomas may be hyperplastic responses of eccrine ducts to inflammatory dermatoses, in contrast to actual neoplasms.26 Guitart et al.26 suggested the classification as “syringomatous dermatitis” in such cases.

Issue Number: 
6_2005
author: 
By Michael H. Davidian, M.D., Dominik Starosta, B.S., Carlos Rodriguez, M.D., and Gary A. McCracken, M.D

Patient presentation
A 53-year-old Caucasian man was referred to our dermatology clinic by his primary care physician for the evaluation of a longstanding slightly pruritic papular eruption. The eruption appeared initially on his arms, then subsequently spread to involve his scalp, face, chest, abdomen and back over a period of 7 years. During this period, multiple crops of similar lesions appeared sequentially on the involved body areas. He had been treated with ciclopirox cream (Loprox) for a presumptive diagnosis of tinea versicolor with no improvement.

His past medical history was significant only for diabetes mellitus and rosacea. He denied the use of any new medications or topical products.

On physical examination, multiple translucent to yellow papules were observed on the patient’s face, scalp, arms, chest and back. Scattered erythematous papules and large pores were also seen on his nose and cheeks. A biopsy from a lesion on his left arm was performed, and results are pending.

What is Your Diagnosis?

Diagnosis: Eruptive Syringoma
S yringomas are commonly encountered, generally asymptomatic appendageal hamartomas found primarily on the face and around the eyes. Eruptive forms of these tumors rarely manifest.1,2 The uncommon eruptive morphology of syringoma, also known as eccrine or eruptive hidradenoma, was first described by Jacquet and Darier in 1887,3 and presents with an abrupt onset of multiple lesions appearing in successive crops on the anterior chest, neck, abdomen, axillae, proximal inner surfaces of the extremities, and/or groin areas. Adolescent and young adult patients are most frequently affected, but the eruption may also occur in young children.4 Eruptive syringoma is commonly chronic and persistent.1,5 Lesions may spontaneously resolve, but most patients experience progressive spread of the
eruption over several years.5 The risk of recurrence, even following successful
treatment, cannot be eliminated.

Clinicopathologic Characteristics of Eruptive Syringoma
Syringomas are benign adnexal neoplasms that arise from the intraepidermal portions of eccrine sweat ducts, and encompass four clinical variants: a localized form, a familial variant, a form associated with Down syndrome, and a generalized type comprised of multiple, eruptive morphologies.6 Lesions are 1-mm to 5-mm translucent to yellow, or flesh-colored to light brown or hyperpigmented papules on the eyelids and face. Symmetrically oriented acral lesions may occur on the wrists and forearms.7

Syringomas, usually asymptomatic, are more common in Caucasians and in adult females at puberty or near middle-age.7-9 Japanese females and Down syndrome patients have a higher incidence of the disease, particularly involving the eyelid.10,11 Syringomas have been found in association with melanocytic nevi, as well as those occurring with milia-like idiopathic calcinosis cutis (MICC).7,12 A link with Ehlers-Danlos syndrome, Marfan’s disease, and atrophoderma vermiculata has also been documented,13 as has scarring and non-scarring alopecia.14,15 The occurrence of eruptive syringoma in conjunction with milia has been documented as well,6,8,16 and may be considered a separate subtype.

Onset of Condition
Generalized eruptive syringoma presents with a sudden onset of successive crops of small skin-colored to brown papules, usually on the anterior aspect of the body during the peripubertal period.17 Unlike other forms of syringoma, eruptive lesions do not show a female preponderance.5 Eruptive syringomas may remain as solitary papules or coalesce into plaques, and are usually asymptomatic, although pruritic lesions may occur more often in warmer months or during mestruation.2,17-19

Rarer forms involve acral and genital sites, in addition to syringomas occurring with other appendageal tumors such as apocrine hidrocystomas.5 An association with diabetes and Down syndrome exists,2,20,21 and the onset of lesions near pubertal age has implicated the possibility of hormonal influence over tumor development.2 Positive expression of progesterone receptors has been identified in eruptive syringomas, but estrogen receptor expression is quite rare.

Theories on the etiology of eruptive syringoma have included effects of high altitude on the sweat apparatus22 and a mast cell-mediated pathogenetic mechanism.23

A clear cell form of eruptive syringoma with glycogen deposition in ducts and positive expression of progesterone receptors has recently been reported in association with diabetes, alluding to possible hormonal influence and decreased or deficient glycogen phosphorylase enzyme in involved skin.2,20

Differential Diagnosis
When syringomas occur in the classic periocular and facial locations, diagnosis is generally straightforward. However, generalized eruptions must be excluded from papular dermatoses in other sites.

In 29 Italian patients studied retrospectively by Patrizi et al.,7 several had lichen planus-like papules, while others showed urticaria pigmentosa-like lesions with positive Darier’s signs.
Occasional mast cells may be seen surrounding syringomas on biopsy and may help explain the similarity of eruptive syringoma with urticaria pigmentosa.27

Other differential diagnoses include xanthomas, flat verrucae, pseudoxanthoma elasticum, steatocystoma multiplex, disseminated granuloma annulare, multiple trichoepitheliomas, eruptive vellus hair cysts, secondary syphilis and even basal cell nevus syndrome.4,9,13,19 Drug eruptions should be ruled out as well.

Treatment Options
Treatment of eruptive syringoma is generally unsatisfactory.1 As syringomas represent epithelial lesions situated in the dermis, excisional techniques are usually required for complete removal, but given their multiplicity, surgery is generally avoided.9 Although several therapeutic options exist, success has been limited.27

Oral retinoids administered over several months are effective in treating eruptive conditions including Cowden syndrome and Muir-Torre syndrome; however, isotretinoin (Accutane) was employed with contrasting results in two reports of eruptive syringoma.5,28

Pruritic lesions may be ameliorated using topical and oral corticosteroids, topical antifungals, and topical retinoids.29 In one case, 1% topical atropine was used successfully.18

Surgical excision, electrocoagulation, electrodessication with curettage, carbon dioxide vaporization, dermabrasion and liquid nitrogen cryotherapy have all been used with some success, although laser treatment has demonstrated somewhat better outcomes.9,30

A recent report of CO2 laser resurfacing after trichloroacetic acid pre-treatment showed acceptable cosmetic results without significant side effects.9 Unfortunately, surgical and chemical lesion destruction may result in scarring and a poor cosmetic result, and neither modality eliminates a recurrence.1,4,5

Our patient was started on desoximetasone (Topicort) cream b.i.d. to affected body areas and metronidazole topical gel (Metrogel) b.i.d. for his rosacea. He has experienced mild improvement.

Call for Cases
If you have a case you’d like to see published, send a write-up (1,200 to 1,500 words) and an image of the patient’s condition to:
Dr. Amor Khachemoune,
Wellman Center for Photomedicine (BAR314)
Department of Dermatology,
Massachusetts General Hospital
Harvard Medical School
40 Blossom Street
Boston, MA 02114
Or, e-mail them to amorkh@pol.net.

Editor(s): 
Amor Khachemoune, M.D., C.W.S.
References: 

References:
1. Hsiung SH. Eruptive syringoma. Dermatol Online J 2003 Oct;9(4):14.
2. Timpanidis PC, Lakhani SR, Groves RW. Progesterone receptor-positive eruptive syringoma associated with diabetes. J Am Acad Dermatol 2003 May;48(5 Suppl):S103-4.
3. Jacquet L, Darier J. Hydradenomes eruptifs, epitheliomes adenoids des glandes sudoripares ou adenomas sudoripares. Ann Dermatol Syph 1887;8:317-23.
4. Pruzan DL, Esterly NB, Prose NS. Eruptive syringoma.
Arch Dermatol 1989 Aug;125(8):1119-20.
5. Janniger CK, Brodkin RH. Eruptive syringomas.
1990 Sep;46(3):247-9.
6. Friedman SJ, Butler DF. Syringoma presenting as milia.
J Am Acad Dermatol 1987 Feb;16(2 Pt 1):310-14.
7. Patrizi A, Neri I, Marzaduri S, Varotti E, Passarini B. Syringoma: a review of twenty-nine cases. Acta Derm Venereol (Stockh) 1998 Nov;78(6):460-2.
8. Weiss E, Paez E, Greenberg AS, et al. Eruptive syringomas associated with milia. Int J Dermatol 1995 Mar;34(3):193-5.
9. Frazier CC, Camacho AP, Cockerell CJ. The treatment of eruptive syringomas in an African American patient with a
combination of trichloroacetic acid and CO2 laser destruction. Dermatol Surg 2001 May;27(5):489-92.
10. Schepis C, Torre V, Siragusa M, et al. Eruptive syringomas with calcium deposits in a young woman with Down’s
syndrome. Dermatology 2001;203(4):345-7.
11. Urban CD, Cannon JR, Cole RD. Eruptive syringoma in Down’s syndrome. Arch Dermatol 1981 Jun;117(6):374-5.
12. Schepis C, Siragusa M, Palazzo R, Batolo D, Romano C. Perforating milia-like idiopathic calcinosis cutis and periorbital sryingomas in a girl with Down syndrome. Pediatr Dermatol
1994 Sep;11(3):258-60.
13. Dyall-Smith DJ, Connors TJ, Scurry J. Generalized eruptive syringoma- a papular dermatosis. Australas J Dermatol 1990;31(2):95-8.
14. Dupre A, Bonafe JL, Christol B. Syringomas as a causative factor for cicatricial alopecia. Arch Dermatol 1981 Jun;117(6):315.
15. Neuman KM, Burnett JW. Alopecia associated with
syringomas. J Am Acad Dermatol 1985 Sep;13(3):528-9.
16. Wenyuan Z. Syringoma associated with milium-like lesions. J Am Acad Dermatol 1988 Aug;19(2 Pt 1):360-1.
17. Lee AY, Kawashima M, Nakagawa H, Ishibashi Y. Generalized eruptive syringoma. J Am Acad Dermatol 1991 Sep;25(3):570-1.
18. Sanchez TS, Dauden E, Casas AP, Garcia-Diez A. Eruptive pruritic syringomas: treatment with topical atropine.
J Am Acad Dermatol 2001 Jan;44(1):148-9.
19. Hashimoto K, DiBella RJ, Borsuk GM, Lever WF. Eruptive hidradenoma and syringoma. Histological, histochemical, and electron microscopic studies. Arch Dermatol 1967 Nov;96(5):
500-19.
20. Kudo H, Yonezawa I, Ieki A, Miyachi Y. Generalized
eruptive clear-cell syringoma. Arch Dermatol 1989 Dec;125(12):1716-7.
21. Rhodes L, Verbov J. Widespread syringomata in Downs
syndrome. Clin Exp Dermatol 1993 Jul;18(4):333-4.
22. White CJ. Syringocystoma. J Cutan Dis 1907;25:412-6.
23. Claudy AL. Adult onset urticaria pigmentosa and eruptive syringomas. J Am Acad Dermatol 1988 Jul;19(1 Pt 1):135.
24. Feibelman CE, Maize J. Clear cell syringoma: a study by conventional and electron microscopy. Am J Dermatopathol
1984 Apr;6(2):139-50.
25. Hashimoto K, Blum D, Fukaya T, et al. Familial syringoma. Case history and application of monoclonal anti-eccrine gland antibodies. Arch Dermatol 1985 Jun;121(6):756-60.
26. Guitart J, Rosenbaum MM, Requena L. ‘Eruptive
syringoma’: a misnomer for a reactive eccrine gland ductal proliferation? J Cutan Pathol 2003 Mar;30(3):202-5.
27. Mertz H, Veien NK. Eruptive syringoma mimicking urticaria pigmentosa. Acta Derm Venereol (Stockh) 1993 Apr;73(2):136-7.
28. Mainitz M, Schmidt JB, Gebhart W. Response of multiple syringomas to isotretinoin. Acta Derm Venereol (Stockh) 1986;66(1):51-5.
29. Gomez MI, Perez B, Azana JM, Nunez M, Ledo A. Eruptive syringoma: treatment with topical tretinoin. Dermatology 1994;189(1):105-6.
30. Apfelberg DB, Maser MR, Lash H, et al. Superpulse CO2 laser treatment of facial syringomata. Lasers Med Surg 1987;7(6):533-7.

0
No votes yet

REVIEW OUR OTHER
HEALTHCARE BRANDS

Check out our other resources for healthcare professionals of all specialties.

  • WOUNDS
  • Todays Wound Clinic
  • Podiatry Today
  • Ostomy Wound Management